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Abstract 
Introduction: Pituitary enlargement has been reported in individuals with schizophrenic 
psychosis or an at-risk mental state for psychosis (ARMS). In a previous study, our group 
could show pituitary volume increase in first episode and ARMS patients with later transition 
to psychosis (ARMS-T). However, there are no longitudinal studies on this issue so far. We 
therefore examined longitudinally whether transition to psychosis would be accompanied by a 
further increase of pituitary volume in antipsychotic-naïve ARMS patients. 
Methods: Magnetic resonance imaging (MRI) data were acquired from 23 antipsychotic-
naïve individuals with an ARMS. Ten subjects developed psychosis (ARMS-T) and 13 did 
not (ARMS-NT). ARMS-T were re-scanned after the onset of psychosis, ARMS-NT at the 
end of the study period.  
Results: There was no significant difference of the pituitary volume between ARMS-T and 
ARMS-NT in our sample and there were no significant pituitary volume changes over time.  
Discussion: Longitudinally, we could not detect any further volumetric changes in the 
pituitary volume with transition to psychosis.  
Conclusions: This, together with the result of our previous study, could indicate that the 
perceived level of stress in ARMS patients is constantly high from very early onwards. 
 
Keywords: schizophrenic psychoses; hypothalamic-pituitary-adrenal axis (HPA-axis); stress; 
prolactin; ACTH; neuroimaging  
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Introduction 
Enlargement of the pituitary gland has been reported in schizophrenic psychoses and patients 
with an at-risk mental state for psychoses (ARMS).
1
  
Cross-sectional studies indicate that pituitary volume (PV) is increased at psychosis onset
2
 
and even in the prodromal stage of the disease.
1,3
 This enlargement seems to be more 
pronounced in ARMS with later transition to psychosis compared to ARMS without transition 
to psychosis.
3
 PV seems to be further increased by most antipsychotics
4
 through lactotroph 
hyperplasia.
5
 
Studies with chronic schizophrenia patients suggest that initial enlargement is followed by a 
decrease of PV.
4,6
 The decrease following the initial enlargement has not only been found in 
treated
4
 but also in untreated
7
 patients and might be caused amongst others by a chronic 
activation of the HPA axis.
4,8
 
Results of longitudinal MRI studies are less consistent than those of cross-sectional studies 
due to different types of medications at baseline and during follow-up, as well as to the length 
of the follow-up. To our knowledge, only four longitudinal MRI studies on PV changes in 
first episode psychosis (FEP) patients have been conducted. MacMaster et al.
9
 found a 12% 
increase in an originally antipsychotic-naïve population with schizophrenia, possibly driven 
by the prolactin-elevating antipsychotic risperidone (follow-up period 12 months). Takahashi 
et al.
10
 also found an enlargement over time in 18 FEP and 13 schizotypical disorder patients 
(all on antipsychotic treatment at baseline and follow-up) over a follow-up period of 
approximately 2.7 years. The third study
11
 showed a dose-dependent reduction of PV in 
patients with atypical antipsychotic medication during a 3-months follow-up. As in this study 
mostly quetiapine was used, which does not induce hyperprolactinemia, this might reflect the 
“natural course” of PV development. A recently published study in 55 FEP patients did not 
find changes in PV following antipsychotic treatment.
12
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However, to date, there are no longitudinal studies on PV changes in ARMS individuals. 
Hence, this study aimed to elucidate how PV changes develop during emerging psychosis. 
Specifically, we aimed to investigate PV changes associated with the onset of psychosis by 
comparing subjects with an ARMS with later transition to psychosis (ARMS-T) versus those 
without transition (ARMS-NT).  In longitudinal analysis, we expected to find a progression of 
PV enlargement in ARMS-T compared to ARMS-NT as stress on the one hand is known to 
trigger the transition to psychosis and on the other hand to increase PV due to activation of 
ACTH and prolactin synthesis.
3,6,13-17
 
Methods  
Study design 
This imaging study was embedded in the Früherkennung von Psychosen (FePsy) study which 
is an open, prospective clinical study of all consecutive referrals to a specialized clinic for the 
early detection of psychosis.
18,19
 From March 1, 2000, to February 29, 2004, individuals with 
suspected ARMS were identified and investigated in various modalities, including 
psychopathology and neuropsychology. Follow-up assessments of all ARMS individuals were 
conducted at regular intervals (see below). 
Setting 
Subjects were recruited through the FePsy Early Detection Clinic at the University 
Psychiatric Outpatient Department, Basel, Switzerland, a clinic specifically designed to 
identify ARMS. To encourage early, low-threshold referrals, widespread information 
campaigns targeting potential referring professionals and lay people were conducted.
18
 All 
referrals to the clinic during the study period were screened as described below. 
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The study was described comprehensively to the subjects and written informed consent was 
obtained as per approved guidelines from the University of Basel local ethics committee 
(EKBB). 
Inclusion criteria 
Inclusion as ARMS required one or more of the following: (a) “attenuated” psychotic 
symptoms (scores of 2 or 3 on the hallucination item, 3 or 4 on the unusual thought content or 
3 or 4 on the suspiciousness items of the BPRS
20
 for at least several times a week and 
persisting for more than 1 week), (b) brief limited intermittent psychotic symptoms (BLIPS) 
(scores of 4 or above on the hallucination item, or 5 or above on the unusual thought content, 
suspiciousness or conceptual disorganization items of the BPRS, with each symptom lasting 
less than 1 week before resolving spontaneously), (c) a first degree relative with a psychotic 
disorder plus at least two indicators of a clinical change, such as marked decline in social or 
occupational functioning, or (d) minimal amount and combination of unspecific risk factors 
according to the Basel Screening Instrument for Psychosis (BSIP)
21
 and proficiency in the 
German language. 
Exclusion criteria 
These were: age below 18 years, insufficient knowledge of German, IQ < 70, previous 
episode of diagnosed and treated schizophrenic psychosis or treatment with antipsychotics for 
more than 3 weeks (lifetime) equivalent to a chlorpromazine dose of 2500 mg,
22
 psychosis 
due to organic brain disease including substance dependency, or psychotic symptoms within a 
clearly diagnosed affective disorder or borderline personality disorder. For this part of the 
study only patients with normal thyroid function were included. When it was not suitable to 
perform an MRI (e.g. pacemaker, metal in the body), subjects were excluded from the 
imaging part of the FePsy study. 
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Measures 
Screening Instrument 
The ARMS was assessed using the BSIP, which was specifically developed for this purpose.
21
 
The BSIP is based on the DSM-III-R prodromal symptoms and other prodromes as derived 
from literature as well as social decline, drug abuse, previous psychiatric disorders, and 
genetic risk; four psychosis items of the expanded version of the BPRS
20
 for assessing (pre-) 
psychotic phenomena were incorporated. The BSIP allows the rating of individuals regarding 
inclusion/exclusion criteria corresponding to the PACE (Personal Assessment and Crisis 
Evaluation) criteria
23,24
 and has been shown to have a good inter-rater reliability for the 
assessment of the main outcome category "at risk for psychosis" and a high predictive 
validity.
21
 
Entry Examination 
All subjects selected for the study by screening subsequently underwent an extensive entry 
examination, which included the BPRS and the Scale for the Assessment of Negative 
Symptoms (SANS).
25
 
Follow-Up 
Each ARMS individual was followed up at regular intervals. During the first year of follow-
up, high-risk individuals were assessed monthly using BPRS and SANS. During the second 
and third years, all individuals were assessed every 3 months and thereafter once annually. 
Transition to psychosis was monitored, applying the transition criteria of Yung et al.
23
 
Subjects 
For this study, 23 antipsychotic-naïve individuals with an ARMS were included. Applying the 
above mentioned transition criteria, 10 of the 23 ARMS individuals made the transition to 
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psychosis (ARMS-T) during follow-up and 13 did not transition to psychosis during the 
follow-up period (ARMS-NT). The relatively high transition rate (43%) is explained by the 
method we chose the patients. Of our original sample of ARMS patients
3
 we chose the first 10 
patients with transition to psychosis (ARMS-T) and invited them for a follow-up scan. The 
group of ARMS-NT was then matched to the group of ARMS-T in terms of age, gender, and 
education. Mean follow-up periods were 1034 and 1689 days in ARMS-T and ARMS-NT, 
respectively. 
Baseline MRIs are part of our cross-sectional hippocampal volume study
26
 and the sample 
partly overlaps with the sample of our longitudinal hippocampal volume study in ARMS.
27
 
Image acquisition 
Subjects were scanned at the time of study inclusion and were re-scanned after the onset of 
psychosis or at the end of the follow-up (approximately 5 years after inclusion to the study) if 
they did not develop psychosis.  
All patients at baseline had 1.5 T scanning, part of the follow-up scans were done with the 3 T 
scanner.  Head movement was minimized by foam padding and Velcro straps across the 
forehead and chin. A three-dimensional volumetric spoiled gradient recalled echo sequence 
generated 176 contiguous, 1-mm thick sagittal slices. Imaging parameters were: time-to-echo, 
3.04-4 ms; time-to-repetition, 1.9-9.7 ms; flip angle, 12-15; matrix size, 200 × 256; field of 
view, 25.6 × 25.6 cm matrix; voxel dimensions, 1 × 1 × 1 mm for the 1.5 T scanner, 
respectively: time-to-echo, 3.37 ms; time-to-repetition, 2 ms; flip angle, 8; matrix size, 256 × 
256; field of view, 25.6 × 25.6 cm matrix; voxel dimension, 1 × 1 × 1 mm for the 3 T scanner. 
 
Image analysis 
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Original DICOM data were then converted to Analyze 7.5 format in axial direction coded to 
ensure blindness of the investigator and patients' confidentiality and finally imported into the 
image-analysis software AMIRA.
28
 
The pituitary glands were manually traced in the interactive public domain software program 
AMIRA using a method described by Sassi et al.
8
 The pituitary stalk was excluded, but the 
posterior pituitary was included. We traced around the borders of the pituitary in the same 
way as previously described:
1,4,9,11
 the diaphragma sellae superiorly, the sphenoid sinus 
inferiorly, and the cavernosus sinus laterally. First, the pituitary was traced in all coronal 
slices where it could be visualized. In addition to the method of Sassi et al.,
8
 the tracing was 
then corrected in sagittal and axial dimensions to be finally controlled on the coronal slices 
again. The software calculates the traced ROI volume in mm
3
 by summing the number of 
voxels of each traced slice. 
All measurements were carried out by a trained and blinded rater (AW). The intra-rater intra-
class correlation coefficient in a subset of 10 randomly selected brains was 0.81. All of our 
baseline scans have been part of the sample published in a cross-sectional investigation of our 
group
3
. Inter-rater reliability was estimated based on 10 randomly selected cases measured in 
our previously published study 
3
and remeasured now by the first author of this paper. The 
inter-rater intra-class correlation was 0.718. 
The whole brain volume was measured to correct for differences in head size as previously 
described.
27,29-31
 
Statistical analysis 
Analyses were performed using the R environment for statistical computing.
32
 Clinical and 
demographic differences between groups were examined with Fisher’s Exact test and Welch 
Two Sample t-test. PV changes over time were analyzed by using a linear mixed effects 
model that included a random intercept factor for the subjects and fixed effects for time, 
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group (ARMS-T vs. ARMS-NT), age, gender, medication, whole brain volume (baseline), 
scanner, and time by group and time by medication interactions. P-values of the ﬁxed effects 
parameters were estimated by using Markov Chain Monte Carlo (MCMC) simulations using 
the pvals.fnc function in the languageR package.
33
 
Results 
Demographic and clinical data 
Regarding sex, age, education, and current cannabis use at baseline, there were no significant 
differences between ARMS with subsequent transition and ARMS without later transition to 
psychosis. However, there was a significantly higher SANS score and a trend towards higher 
BPRS scores already at baseline in ARMS-T compared to ARMS-NT (Table 1). All patients 
were antipsychotic-naïve at baseline, but 6 of the ARMS-T patients were treated with 
antipsychotics (2 olanzapine, 1 risperidone, 1 amisulpride, 1 perphenazine) at the second scan. 
This can be explained by the fact that these patients at transition often had to be treated before 
they could be scanned. The average time between transition and second scan was 802 days. 
All ARMS-NT subjects were still antipsychotic-naïve at the follow-up scan. Compared to 
ARMS-T, the inter-scan (t0 - tx) interval was slightly longer in ARMS-NT (p = 0.015) as we 
wanted to be sure not to miss a transition. 
Pituitary volume 
The mixed effects model revealed significant main effects of sex (p ≤ 0.001), and medication 
(p = 0.005): PVs were significantly larger in women and in patients treated with 
antipsychotics at the second scan. 
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We found no significant main effects of group, age, whole brain volume, scanner, and time by 
group and time by medication interactions. Thus, PV did not change over time in neither 
group when corrected for confounders as described above (i.e. including medication).  
Whole brain volume was significantly smaller in women than in men (Table 2), but not 
significantly different between ARMS-T and ARMS-NT. We also found no significant 
association of whole brain volume with PV (p = 0.103692), and the above mentioned results 
did not change whether we considered whole brain volume or not.  
Correlational analyses 
In a next step, we tested whether PV was associated with the severity of psychopathological 
symptoms. PV did not significantly correlate with BPRS total score (r = 0.1, t = 0.44, df = 18, 
p = 0.662) or SANS total score (r = 0.12, t = 0.51, df = 18, p = 0.61), even if we only included 
ARMS-T (r = -0.06, t = -0.16, df = 8, p-value = 0.874 and r = 0.07, t = 0.21, df = 8, p-value = 
0.838, respectively). 
Discussion 
To our knowledge, this is the first longitudinal study investigating PV in an antipsychotic-
naïve ARMS population comparing ARMS with subsequent transition to psychosis versus 
ARMS without transition. 
We studied 23 antipsychotic naïve individuals with an ARMS within the FePsy study at 
baseline. Patients were followed up until transition to psychosis (ARMS-T) or, if they did not 
develop psychosis (AMRS-NT), until the end of the study.  
In contrast to our hypothesis, we did not find a time dependent longitudinal PV increase in the 
ARMS-T group from baseline to transition. Cross-sectionally we had shown a stronger PV 
enlargement in ARMS with later transition to psychosis than in ARMS without later transition 
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and compared to healthy controls (HC) in a previous study of our group
3
. The sample partly 
overlaps, with the one presented here. A recently published cross-sectional study found no 
difference between ARMS with and without later transition to psychosis.
34
 We had 
hypothesized that the enlargement at baseline was due to stress-induced ACTH and prolactin 
synthesis. Based on our current finding of no further PV increase during actual transition to 
psychosis one might conclude that the perceived level of stress in ARMS patients is already 
high at first presentation to special early detection clinic and remains constantly high 
thereafter. As we have no objective measures of stress in our study this remains speculative.  
Alternatively, the lack of a further longitudinal PV increase might be due to methodological 
limitations: due to the long period (on average 802 (±722) days) between transition to 
psychosis and follow-up scan in ARMS-T, we might have missed the expected additional 
stress-induced peak of PV on the time point of transition. A decrease of PV during the later 
course of schizophrenic psychoses has been described before in medicated
4,6
 and 
unmedicated
7
 patients. 
Currently, the stress-vulnerability model is commonly accepted in psychotic disorders.
35-37
 
The literature provides some evidence that the onset of psychotic disorders may be associated 
with a higher rate of stress. One biological system triggered by stress exposure is the 
hypothalamic–pituitary–adrenal (HPA) axis. There is evidence for dysfunction of this system 
in schizophrenic diseases.
15,38-42
 We assume that pituitary volume is a structural means of its 
activity in patients with psychosis.
11
 Indeed, pituitary volume has been used as an indirect 
index of HPA axis activity because it is thought to increase with the number or size of 
corticotrophin-releasing cells (i.e., corticotrophs) in the pituitary gland.
1,4,43-45
 Volumetric 
abnormalities of the pituitary gland in psychotic disorders strengthen this theory.
46 
Nonetheless, there are some contradictory results,
11
 but most studies showing smaller PVs 
were conducted in patients with a chronic type of schizophrenic psychosis.
4,7,47
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We hypothesize that prolactin as a stress hormone can be involved in the increase of PV, but 
it remains unclear what is its cause and its consequence. Previously, PV enlargement in 
schizophrenic psychoses has only been associated with prolactin-increasing antipsychotics.
2,9
 
However, even before antipsychotics were discovered, gonadal dysfunction in schizophrenic 
patients has been reported; for review see Riecher-Rössler & Häfner 1993.
48
 This fact could 
indicate that hyperprolactinemia, which suppresses gonadal function, could be a stress-
induced phenomenon in schizophrenic psychoses which is independent of 
antipsychotics.
3,14,49-51
 As prolactin is produced in the lactotroph cells of the pituitary gland, 
this could also explain PV increase in unmedicated ARMS individuals. Hyperprolactinemia in 
antipsychotic-naïve ARMS individuals
14
 and first episode psychosis patients
13,14,52,53
 has been 
shown before.  
There are only four longitudinal studies on PV in patients with schizophrenic 
psychoses,
9,11,12,54
 but none in ARMS individuals and none with a follow-up period of more 
than 2.7 years. The strength of our study is that we did the first longitudinal study of PV in 
ARMS. Also, all patients at baseline were unmedicated, and the follow-up period was very 
long, so we can be quite sure not to have missed a transition to psychosis. 
PVs were significantly larger in patients who were treated with antipsychotics at time of 
follow-up; this result is consistent with previous results.
4,5
 It has been assumed that the 
pituitary gland is especially sensitive to prolactin-elevating antipsychotics.
9,55
 There are also 
results showing that “atypical” antipsychotics – not further differentiated – correlate with a 
less severe pituitary enlargement.
10
 We have controlled statistically for the influence of 
antipsychotic intake. However, our sample was too small to differentiate between different 
types of antipsychotics. Other causes of pituitary enlargement, such as hypothalamic tumor, 
pregnancy, and primary hypothyroidism
56
 were excluded in our sample. 
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In this study women had larger PVs than men. These findings are consistent with previous 
reports of sex differences in PV, with PVs being larger in healthy women than in men.
57-59
  
According to the stress hypothesis, we would have expected a positive relationship between a 
higher BPRS or SANS total score, implying a higher level of stress to be associated with 
increased PV. However, we did not find significant correlations between clinical symptoms 
(BPRS and SANS) and pituitary volume, which has previously been described also by 
others.
9,45
 In our case, this might be because we measured BPRS and SANS only at baseline 
and psychopathology can change rapidly. 
Many previous studies,
6,9,60,61
 but not all,
62
 have provided evidence that pituitary volume 
reflects hormonal activity. Hence, we chose a volumetric approach to evaluate the hormonal 
function. Other studies have provided no evidence for a relation between PV and current basal 
levels of anterior pituitary hormones.
62
 We did not measure hormone levels at the time of scan 
acquisition and therefore do not know if HPA and HPG activity at the time of MRI was really 
abnormal. But we know from another study in our FePsy sample that 24% of our 
antipsychotic-naïve ARMS patients and 33% of our antipsychotic-naïve FEP patients suffered 
from hyperprolactinemia.
14
 
 
In line with other recent studies,
46,63
 we did not distinguish between the anterior and posterior 
part of the pituitary. This might be seen as a potential limitation of our study, but the posterior 
part of the pituitary constitutes only a very small part of the whole gland and no conditions are 
known to influence it in the examined age group.
43
 Thus, it has been hypothesized that the 
whole pituitary volume is representative for the anterior lobe.
64
 
Another limitation might be that the cycle state of the women included in our study was not 
taken into account. However, a recent study has shown that cycle phase, number of given 
births, and onset or duration of menopause have no effects on pituitary size.
61
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Last but not least, small effects might have been overlooked due to our obviously small 
sample size and limited power. In order to estimate the likelihood of a type II error, we would 
have to conduct a formal power analysis. However, since there are no longitudinal studies on 
pituitary volume changes in ARMS patients, let alone meta-analyses, we cannot make a 
reliable assumption about the pituitary volume change in the population of ARMS patients in 
a specific amount of time and thus are unable to do a proper power analysis. Doing a post hoc 
power analysis by taking the effect size that we have measured in our own sample as a 
population effect size estimate would be very inappropriate and has strongly been criticized.
65
 
Hopefully, our study could still contribute to the detection of small effects in the future if data 
will be included into meta-analyses. 
Further studies should include: anatomical scanning at the time transition, additional 
measurements of hormones (prolactin, cortisol), comparisons with other diseases, a healthy 
control group with longitudinal measurements, and larger samples. 
Conclusions 
Pituitary enlargement has been reported in individuals with schizophrenic psychosis or an at-
risk mental state for psychosis (ARMS). To our knowledge, this is the first longitudinal study 
investigating PV in an antipsychotic-naïve ARMS population comparing ARMS with 
subsequent transition to psychosis versus ARMS without transition. Only partly supporting 
our hypothesis, we did not find a time-dependent PV increase in the ARMS-T group from 
baseline to transition. This might indicate that the perceived level of stress in ARMS patients 
is constantly high from very early onwards. Further studies should include: anatomical 
scanning at the time transition, additional measurements of hormones (prolactin, cortisol), 
comparisons with other diseases, a healthy control group with longitudinal measurements, and 
larger samples. 
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TABLE 1. Sociodemographic and clinical sample description 
 
ARMS-NT  
(n = 13) 
ARMS-T  
(n = 10) 
Group 
comparisons 
Sex 
  Women 
  Men 
 
n = 5 (38%) 
n = 8 (62%) 
 
n = 3 (30%) 
n = 7 (70%) 
p = 1
1
 
Age at baseline scan, mean [years] (SD) 23.1 (5.7) 25.3 (6.7) p = 0.43
2
 
Education, mean [years] (SD) 10.8 (3.3) 10.80 (1.6) p = 0.99
2
 
BPRS total score at baseline  37.1 (6.9) 43.8 (8.7) p = 0.077
2
 
SANS total score at baseline 16.4 (11.5) 32.9 (20.4) p = 0.049
2
 
Antipsychotic intake at baseline scan 0% 0%  
Antipsychotic intake at 2nd scan n = 0 (0%) n = 6 (60%) p = 0.002
1
 
Inter-scan interval t0-tx, mean [days] (SD) 1689 (438) 1034 (648) p = 0.015
2
 
Time between transition and 2
nd
 scan, mean 
[days] (SD) 
- 802 (722)  
Cannabis use at baseline   p = 0.28 
None 53% 75%  
Rarely 7% 12%  
Several times per month 7% 0%  
Several times per week 13% 0%  
Daily 20% 12%  
SANS = Scale for the Assessment of Negative Symptoms;
25
 BPRS = Brief Psychiatric Rating Scale
20
 
1
Fisher’s Exact test 
2
Welch Two Sample t test 
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TABLE 2. Pituitary and whole brain volume by group 
 ARMS-NT 
n = 13 
ARMS-T 
n = 10 
Group comparison 
PV at 1
st
 scan 0.540 (0.055) 0.581 (0.110) t = -0.9, p = 0.3
1 
PV at 2
nd
 scan 0.573 (0.094) 0.617 (0.046) t = -0.2, p = 0.42
1
 
WBV at 1
st
 scan 1313 (116) 1299 (114) t = 4.1, p = 0.78
1
 
Data are presented as mean [ml] (SD); PV = pituitary volume; WBV = whole brain volume 
1
Welch Two Sample t test 
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TABLE 3. Gender differences. Pituitary and whole brain volume by group  
  Women Men Group comparison 
ARMS-NT PV at 1
st
 scan 0.58 (0.04) (n = 5) 0.51 (0.04) (n = 8) t = 3.1, p = 0.012
1
 
PV at 2
nd
 scan 0.65 (0.03) 0.52 (0.09) t = 3.8, p = 0.004
1
 
WBV at 1
st
 scan 1221 (99) 1371 (87) t = -2.8, p = 0.025
1
 
ARMS-T PV at 1
st
 scan 0.72 (0.04) (n = 3) 0.52 (0.07) (n = 7) t = 5.4, p = 0.001
1
 
PV at 2
nd
 scan 0.79 (0.09) 0.54 (0.09) t = 4, p = 0.022
1
 
WBV at 1
st
 scan 1181 (81) 1350 (85) t = -3, p = 0.039
1
 
Data are presented as mean [ml] (SD); PV = pituitary volume; WBV = whole brain volume 
1
Welch Two Sample t test 
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FIGURE 1. Volume changes of the pituitary gland in patients with an ARMS without 
transition (ARMS-NT) and with transition to psychosis (ARMS-T). Values of baseline and 
follow-up scans in each subject are connected with a straight line. 
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